SHELTON, Conn., Jan. 2, 2019 /PRNewswire/ -- NanoViricides,
Inc. (NYSE AMER: NNVC) (the "Company"), a pioneer in
developing anti-viral nanomedicine drugs, today announced it will
be featured as a presenting company at the Biotech
ShowcaseTM Investor Conference. The conference is being
held on January 7-9, 2019 at the
Hilton Union Square Hotel in San
Francisco, CA.
Irach B. Taraporewala, Ph.D., CEO of NanoViricides, Inc., will
provide an overview of the Company's business and recent progress
in moving the company drug pipeline forward towards an
Investigational New Drug (IND) Application during the presentation.
He will be available to participate in one-on-one meetings with a
number of investors who are registered to attend this conference
and also interested parties attending the JP Morgan Conference
being concomitantly held in San
Francisco.
Event: Biotech ShowcaseTM Investor Conference
Presentation Date: Monday, January 7,
2019
Presentation Time: 9:30 AM PST
Location: Hilton Union Square Hotel, San
Francisco, CA Yosemite C Room (Ballroom Level)
The Biotech ShowcaseTM Conference hosts presentations
by over 400 biotechnology and pharmaceutical companies in the
microcap and mid-cap range and attracts a wide investor base.
About NanoViricides
NanoViricides, Inc. (www.nanoviricides.com) is a development
stage company that is creating special purpose nanomaterials for
antiviral therapy. The Company's novel nanoviricide® class of drug
candidates are designed to specifically attack enveloped virus
particles and to dismantle them. The Company is developing drugs
against a number of viral diseases including VZV, HSV-1, HSV-2.,
H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and
genital Herpes, viral diseases of the eye including EKC and herpes
keratitis, Dengue fever, and Ebola virus, among others. This
press release contains forward-looking statements that reflect the
Company's current expectation regarding future events. Actual
events could differ materially and substantially from those
projected herein and depend on a number of factors. Certain
statements in this release, and other written or oral statements
made by NanoViricides, Inc. are "forward-looking statements" within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. You should not
place undue reliance on forward-looking statements since they
involve known and unknown risks, uncertainties and other factors,
which are, in some cases, beyond the Company's control and which
could, and likely will, materially affect actual results, levels of
activity, performance or achievements. The Company assumes no
obligation to publicly update or revise these forward-looking
statements for any reason, or to update the reasons actual results
could differ materially from those anticipated in these
forward-looking statements, even if new information becomes
available in the future. Important factors that could cause actual
results to differ materially from the company's expectations
include, but are not limited to, those factors that are disclosed
under the heading "Risk Factors" and elsewhere in documents filed
by the company from time to time with the United States Securities
and Exchange Commission and other regulatory authorities.
Although it is not possible to predict or identify all such
factors, they may include the following: demonstration and proof of
principle in preclinical trials that a nanoviricide is safe and
effective; successful development of our product candidates; our
ability to seek and obtain regulatory approvals, including with
respect to the indications we are seeking; the successful
commercialization of our product candidates; and market acceptance
of our products.
FDA refers to US Food and Drug Administration. EMA refers to the
European Union's office of European Medical Agency.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/nanoviricides-inc-ceo-dr-taraporewala-to-present-at-the-biotech-showcase--investment-conference-in-san-francisco-on-january-7-2019-300771702.html
SOURCE NanoViricides, Inc.